Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000273735 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases.
Biomolecules
January 2025
Institute for Biostructure and Bioimaging, National Research Council, Molecular Biotechnology Centre "Guido Tarone", 10126 Turin, Italy.
Chronic hepatobiliary damage progressively leads to fibrosis, which may evolve into cirrhosis and/or hepatocellular carcinoma. The fight against the increasing incidence of liver-related morbidity and mortality is challenged by a lack of clinically validated early-stage biomarkers and the limited availability of effective anti-fibrotic therapies. Current research is focused on uncovering the pathogenetic mechanisms that drive liver fibrosis.
View Article and Find Full Text PDFCharacterization and Detection Strategy Exploration in Cryptogenic Hepatocellular Carcinoma: Insights From a Super-Aged Region in Japan.
Cancer Med
January 2025
Division of Gastroenterology and Nephrology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
Background And Aim: In recent years, there has been a rise in cryptogenic hepatocellular carcinoma (c-HCC) cases in Japan, posing a detection challenge due to an unknown etiology. This study aims to enhance diagnostic strategies for c-HCC by analyzing its characteristics and exploring current opportunities for detection.
Methods: A retrospective study was conducted from April 2012 to March 2022, enrolling 372 newly diagnosed hepatocellular carcinoma (HCC) patients.
AI in Hepatology: Revolutionizing the Diagnosis and Management of Liver Disease.
J Clin Med
December 2024
Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA 30322, USA.
The integration of artificial intelligence (AI) into hepatology is revolutionizing the diagnosis and management of liver diseases amidst a rising global burden of conditions like metabolic-associated steatotic liver disease (MASLD). AI harnesses vast datasets and complex algorithms to enhance clinical decision making and patient outcomes. AI's applications in hepatology span a variety of conditions, including autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, MASLD, hepatitis B, and hepatocellular carcinoma.
View Article and Find Full Text PDFCharacteristic Histology of Autoimmune Hepatitis-Primary Biliary Cholangitis.
Mayo Clin Proc
December 2024
Division of Anatomic Pathology, Mayo Clinic, Rochester, MN.
Unexplained Chronically Elevated Aminotransferases: Liver Biopsy Gives Major Information with Therapeutic Implication in One Patient Out of Seven.
Dig Dis Sci
December 2024
Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, Paris, France.
Article Synopsis
- The study aimed to evaluate the importance of liver biopsy in patients with unexplained elevated transaminases, following current clinical guidelines.
- A retrospective analysis of 87 patients revealed that 48% had minimal or normal liver tissue changes, while different injury patterns were identified in varying percentages: steatosis (21%), hepatitis (13%), vascular (8%), and biliary (1%).
- Ultimately, liver biopsy significantly impacted clinical management in 15% of cases, helping diagnose conditions like autoimmune hepatitis and metabolic dysfunction, but most patients showed little to no significant pathology.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!